share_log

Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $5 Price Target

Benzinga ·  May 31 22:59

Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment